Publications by authors named "Miles Prince"

Claim this Profile
P
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
Elżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, H Miles Prince

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Langerhans cell histiocytosis presenting in the skin in adults: Clinical patterns and outcomes with skin-directed therapy.
Jennifer Ward, H Miles Prince, Christopher J McCormack, Stephen Lade, Christine Khoo

J Am Acad Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy Utilization for Primary Cutaneous T-Cell Lymphoma Is Lowest Among Patients Living in the Most Geographically Accessible Areas: An Australian Study.
Belinda A Campbell, Gabriel Gabriel, Geoff P Delaney, Sandro V Porceddu, Robert Smee, H Miles Prince

Int J Radiat Oncol Biol Phys· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas.
Daniel Fasser, Greta Joy, Mark R Dowling, Ketan Bavishi, Andreas Kiesbye Øvlisen, H Miles Prince

Leuk Lymphoma· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy dose-response of mycosis fungoides with large cell transformation.
Martin J Higgins, Philippa Johnstone, H Miles Prince, Stephen Lade, Michael T Fahey

Radiother Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.
Joshua M L Casan, Xiao Jing Ong, Carrie van der Weyden, Costas K Yannakou, Joe Zhu, H Miles Prince

J Pers Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium.
Mark N Sorial, Luis Malpica, Carlos Sergio Chiattone, Edith Julia, Emmannuel Bachy, H Miles Prince

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.
Georgia McCaughan, Hayley Beer, Christian Bryant, P Joy Ho, Tracy King, H Miles Prince

Intern Med J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refractory coeliac disease or something else?
Penelope McKelvie, Mandeep Singh, David M Iser, H Miles Prince, Mohammad Ali Bazargan

Pathology· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.
Philippa Johnstone, Martin Higgins, H Miles Prince, Stephen Lade, Chris McCormack

Br J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allergic disease and risk of multiple myeloma: A case-control study.
Simon Cheah, Adrian J Lowe, Nina Afshar, Julie K Bassett, Fiona J Bruinsma, H Miles Prince

Cancer Epidemiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome.
Friyana K Bhabha, Carrie Van Der Weyden, Joshua M L Casan, Belinda A Campbell, Christopher McCormack, H Miles Prince

Expert Rev Clin Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Hang Quach, Gurdeep Parmar, Enrique M Ocio, Miles Prince, Albert Oriol

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geospatial analyses demonstrate variation of cutaneous T-cell lymphomas across Australia, providing insights into possible causes.
Belinda A Campbell, Peter D Baade, Paramita Dasgupta, Jessica K Cameron, Sandro V Porceddu, H Miles Prince

Br J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, H Miles Prince

Nat Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, H Miles Prince

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, H Miles Prince

Nat Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete skin remission of Sneddon-Wilkinson disease with acalabrutinib.
Harmeet K Bhullar, Friyana Bhabha, Chris McCormack, H Miles Prince

Australas J Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024.
Belinda A Campbell, H Miles Prince, Karin Thursky, Bouthaina Dabaja, Richard Hoppe

Semin Radiat Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Hang Quach, Gurdeep Parmar, Enrique M Ocio, H Miles Prince, Albert Oriol

Haematologica· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.
Belinda A Campbell, Gabor Dobos, Zahra Haider, Martine Bagot, Felicity Evison, H Miles Prince

Br J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Belinda A Campbell, H Miles Prince, Julia J Scarisbrick

EClinicalMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting TAG-72 in cutaneous T cell lymphoma.
Vera J Evtimov, Maree V Hammett, Aleta Pupovac, Nhu-Y N Nguyen, Runzhe Shu, H Miles Prince

Heliyon· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Michael H Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, H Miles Prince

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis